Vitals RX: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://vitalsrx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide. As described below, your claim concerning compounded semaglutide and tirzepatide products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The following claim appears on your website, where the only semaglutide and tirzepatide products offered are compounded: • “Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic””

2. 2

   “Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

vitalsrx.com did not resolve on 2026-08-09: DNS returned no record for either the apex or the www host, over both http and https. WHOIS shows the registration itself is ACTIVE with a registry expiry of 2027-08-08 but carries a clientHold status, which withholds a domain from DNS while leaving it registered; vedzilla.com, the contact domain on the letter, returned "No match" from WHOIS. A held domain can be restored and a business can move, so this is recorded as unknown rather than ceased-operations.

What FDA cited here was not a promise about results — it was the shop's name. "Vitals RX - Semaglutide/Tirzepatide/Ozempic Weight Loss Clinic" reads as a description of a catalogue, and it would be accurate if a brand-name product were among the things for sale. FDA's qualifier is what turns it into a claim: the only semaglutide and tirzepatide offered were compounded, so putting Ozempic in the list told a reader the compounded products were that. It is the cheapest possible version of the borrowed-credibility move, requiring no marketing copy at all, and it survives in places sales copy does not — page titles, search listings, ads. If you arrive at a storefront from a search result mentioning a brand, the thing worth checking is whether the brand is actually sold there. The separate practical point is that the domain FDA reviewed no longer resolves, and the contact domain on the letter has no registration record either. That is not proof the business has closed and we have not recorded it as such, but it does mean there is currently nothing at the address the letter names.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Vitals RX failed to respond.